Establishment Labs Holdings (ESTA) Tests Its Bull Case As Analysts Still See Undervaluation

Establishment Labs Holdings stock performance snapshot

Establishment Labs Holdings (ESTA) has drawn investor attention after recent trading left the stock at $72.30 as of 3 September 2026. That price comes alongside mixed short and longer term return figures.

The stock is down about 3% over the past day and roughly 24% over the past month, while the past 3 months show a decline of about 3%. Over longer horizons, the year to date return is around 5% and the 1 year total return is close to 87%.

Over a 3 year period the total return is about 30%, while the 5 year figure reflects a slight decline of roughly 5%. These moves frame how the market has recently been reassessing Establishment Labs Holdings in relation to its fundamentals and growth profile.

For Establishment Labs Holdings, the share price has pulled back over the past month but still sits comfortably above where it started the year, while the 1 year total shareholder return near 87% reflects the strength of the recent run.

This combination of a year to date share price gain of about 5% and a 1 year total shareholder return close to 87% indicates that earlier optimism has cooled in recent weeks as investors reassess growth potential and risk around the current US$72.30 level.

Spot opportunities moving in a similar way to Establishment Labs Holdings by scanning a hand picked 21 high quality undiscovered gems with solid fundamentals and room for a stronger market rerating.

Given Establishment Labs Holdings has surged over 1 year yet pulled back sharply in recent weeks, does the current US$72.30 level still offer a favourable trade off between upside potential and the risks investors are carrying on this loss making business?

Most Popular Narrative: 29.4% Undervalued

Analysts following Establishment Labs Holdings see a fair value near $102.44, which is well above the recent $72.30 close and frames a growth heavy story.

Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that valuation gap? The narrative leans on fast revenue compounding, margin uplift, and a rich future earnings multiple. Curious which specific assumptions have the biggest impact on that fair value.

Result: Fair Value of $102.44 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Establishment Labs Holdings still faces meaningful risks. These include heavy reliance on its Motiva implant portfolio and the liquidity strain of high expenses and working capital needs.

Find out about the key risks to this Establishment Labs Holdings narrative.

Another view on Establishment Labs Holdings valuation

The analyst narrative points to a fair value near $102.44 and a 29.4% discount, yet our DCF model presents a more muted picture. On that view, Establishment Labs Holdings appears almost exactly in line with estimated fair value at $72.41, only about 0.2% above the recent $72.30 price. Which perspective better reflects the risks around a still loss making business?

For a closer look at how this result is built and what would need to change for the picture to shift meaningfully, Look into how the SWS DCF model arrives at its fair value.

Next Steps

With the story around Establishment Labs Holdings skewing positive, do you want to wait on the sidelines or test the numbers yourself? Take a closer look at the growth drivers that have investors optimistic and weigh them against the risks by reviewing the 3 key rewards

Looking for more investment ideas beyond Establishment Labs Holdings?

If Establishment Labs Holdings has sharpened your appetite for opportunities, do not stop here. The biggest missed gains often come from the ideas you never check.

• Target stocks that combine quality and value by scanning a focused list of 52 high quality undervalued stocks that may offer a more attractive entry profile than the broader market.
• Prioritise sleep at night potential with 79 resilient stocks with low risk scores that score well on resilience so you are not constantly worrying about the next sharp drawdown.
• Hunt for lesser known opportunities using a curated 21 high quality undiscovered gems where strong fundamentals have not yet attracted wide market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com